Call Us: 1.800.873.5297

By

Health Canada Warns of Cardiovascular Risks Associated with Testosterone Therapy Drugs

On July 15, 2014, Health Canada warned patients and healthcare professionals of serious and possibly life-threatening cardiovascular risks associated with testosterone replacement therapies. Health Canada recently completed a safety review of low-testosterone products, which revealed that Low-T product use is linked to heart and blood vessel problems, such as heart attack, stroke, pulmonary embolisms (blood […]

By

Niacin May Be Toxic and Too Risky As Heart Drug, Reports Find

NBC news reports that the B3 vitamin, Niacin, often found in over-the-counter tablets, may cause severe negative side effects and may actually fail to reduce rates of stroke, heart attack, or chest pain. Several studies have shown that Niacin can lower low-density lipoprotein (LDL or “bad cholesterol”) while raising high-density lipoprotein (HDL or “good cholesterol”). […]

By

Low-T Lawsuit Update (MDL 2545): FDA Weighs Data on Testosterone Drugs and Heart Attack Risk

The U.S. Food and Drug Administration (FDA) has called a special advisory committee meeting to discuss the results of two trials that demonstrated an increased risk of heart attack in men using testosterone replacement drugs. The FDA called the meeting after it required new label changes on all testosterone replacement therapies to warn consumers of […]

By

Painkillers May Increase Cardiovascular Risks in Older Women, Study Suggests

According to MSN News, a new study showed that certain categories of painkillers, including the over-the-counter drug Aleve® (naproxen), may increase the risk of heart attack or stroke in older women. The new study found an increase in cardiovascular risks associated with anti-inflammatory drugs (NSAIDs) in which the NSAIDs don’t specifically target the cox-2 enzyme, […]

By

Beleodaq® Drug to Treat Rare Form of Non-Hodgkin Lymphoma Receives Accelerated FDA Approval

On July 3, 2014, the U.S. Food and Drug Administration (FDA) approved Beleodaq® (belinostat) as a treatment for Peripheral T-Cell Lymphoma (PTCL). PTCL is a rare and fast-growing type of Non-Hodgkin Lymphoma (NHL) in which the lymph nodes become cancerous. Beleodaq®, which received accelerated approval, is designed to stop enzymes that contribute to T-cells, a […]

By

Texas Attorney General Joins Other States in Investigating Transvaginal Mesh Products

ABC News in Dallas reports that the Texas Attorney General’s Office has started an investigation of Johnson & Johnson and its subsidiary, Ethicon, for potential deceptive trade violations, including those pertaining to advertising, marketing, promotion, and sale and distribution, of transvaginal mesh products (TVM). Texas will join Washington, California, South Carolina, Ohio, Pennsylvania, Florida, Illinois, […]

By

State of Oregon Settles $4 Million Deceptive Marketing Claims Involving DePuy’s Metal-on-Metal Hip Implants

The Oregonian Newspaper reports that DePuy Orthopaedics Inc. has settled claims with the Oregon Department of Justice (DOJ) involving their metal-on-metal artificial hips over allegations that the manufacturer knowingly marketed the hips that were prone to failure. The devices were designed to accommodate younger hip replacement patients by providing more flexibility and range of motion […]

By

Consumer Reports: Spray-On Sunscreens May Cause Asthma and Allergy Attacks in Children

Consumer Reports warns against the use of spray-on sunscreens for children as the product could put children at risk for asthma or allergy attacks. The warning follows the U.S. Food and Drug Administration’s (FDA) 2011 announcement that it was launching an investigation and study involving the spray-on sunscreen products. The focus of the study is […]

By

FDA Denies Approval for Expanded Use of Blood-Thinning Drug Xarelto®

According to Bloomberg, Johnson & Johnson and Bayer AG have failed to win approval for expanded use from the U.S. Food and Drug Administration (FDA) for its blood-thinning medication, Xarelto®. The FDA voted 10-0 against expanded use of Xarelto®. This denial by the FDA comes after recent reports on the drug’s adverse events, including serious […]

By

FDA Approves Insulin Inhalation Powder, Afrezza®

On June 27, 2014 the U.S. Food and Drug Administration (FDA) approved Afrezza, an insulin powder used to control blood sugar levels in patients with diabetes. Data shows that approximately 25.8 million people in the United States, 8.3% of the population, have diabetes. Afrezza®, a rapid-acting insulin that is to be inhaled at the beginning […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.